Skip to main content
. 2019 Oct;20(10):849–860. doi: 10.1631/jzus.B1900205

Table 2.

Prevalence of the autoantibodies in the non-cGVHD, cGVHD, and healthy control (HC) groups

Autoantibody Positive*
P-value
Non-cGVHD (n=31) cGVHD (n=34) HC (n=32) Non-cGVHD vs. cGVHD HC vs. non-cGVHD HC vs. cGVHD
Any autoantibody 21 (67.7) 25 (73.5) 3 (9.4) 0.506 <0.0003a <0.0001a
ANA (IFA) 17 (54.8) 19 (55.9) 2 (6.2) 0.978 <0.0001a <0.0001a
Anti-U1-nRNP 0 (0.0) 2 (5.9) 0 (0.0) 0.345 0.345
Anti-Sm 0 (0.0) 0 (0.0) 0 (0.0)
Anti-SS-A 4 (12.9) 1 (2.9) 1 (3.1) 0.148 0.148 0.966
Anti-Ro/SS-A 52 kDa 6 (19.4) 6 (17.6) 1 (3.1) 0.772 0.047a 0.049a
Anti-SS-B 0 (0.0) 0 (0.0) 0 (0.0)
Anti-Scl-70 0 (0.0) 0 (0.0) 0 (0.0)
Anti-Jo-1 1 (3.2) 0 (0.0) 0 (0.0) 1.000 1.000
Anti-CENP-A 1 (3.2) 1 (2.9) 0 (0.0) 1.000 1.000 1.000
Anti-CENP-B 2 (6.5) 1 (2.9) 0 (0.0) 0.345 0.500 1.000
Anti-PM-Scl100 0 (0.0) 2 (5.9) 0 (0.0) 0.500 0.500
Anti-PM-Scl75 0 (0.0) 0 (0.0) 0 (0.0)
Anti-PCNA 0 (0.0) 1 (2.9) 0 (0.0) 1.000 1.000
Anti-dsDNA 0 (0.0) 1 (2.9) 0 (0.0) 1.000 1.000
Anti-nucleosomes 0 (0.0) 0 (0.0) 0 (0.0)
Anti-histones 0 (0.0) 3 (8.8) 0 (0.0) 0.173 0.173
Anti-ribosomal P protein 0 (0.0) 0 (0.0) 0 (0.0)
AMA-M2 (LIA) 1 (3.2) 3 (8.8) 0 (0.0) 0.148 1.000 0.173
Anti-RP11 0 (0.0) 0 (0.0) 0 (0.0)
Anti-RP155 1 (3.2) 0 (0.0) 0 (0.0) 1.000 1.000
Anti-fibrillarin 2 (6.5) 0 (0.0) 0 (0.0) 0.345 0.345
Anti-NOR90 0 (0.0) 0 (0.0) 0 (0.0)
Anti-Th/To 0 (0.0) 0 (0.0) 0 (0.0)
Anti-Ku 0 (0.0) 1 (2.9) 0 (0.0) 1.000 1.000
Anti-PDGFR 0 (0.0) 0 (0.0) 0 (0.0)
ACLA 1 (3.2) 0 (0.0) 0 (0.0) 1.000 1.000
Anti-CCP 0 (0.0) 0 (0.0) 0 (0.0)
Anti-PR3 (ELISA) 0 (0.0) 0 (0.0) 0 (0.0)
Anti-MPO (ELISA) 0 (0.0) 3 (8.8) 0 (0.0) 0.159 0.107
Anti-SLA/LP 1 (3.2) 3 (8.8) 0 (0.0) 1.000 1.000 0.148
Anti-LC-1 0 (0.0) 0 (0.0) 0 (0.0)
Anti-LKM-1 0 (0.0) 0 (0.0) 0 (0.0)
*

Data are expressed as number (percentage).

a

Statistical significance between the groups (P<0.05). GVHD, graft-versus-host disease; cGVHD, chronic GVHD; ANA, anti-mitochondrial antibody; nRNP, nuclear ribonucleoprotein; Scl-70, topoisomerase I; Jo-1, histidyl-tRNA synthetase; CENP, centromere protein; PM, polymyositis; PCNA, proliferating cell nuclear antigen; RP, proteinase; NOR90, nucleolar organizing region 90; PDGFR, platelet-derived growth factor receptor; ACLA, anti-cardiolipin antibody; CCP, cyclic citrullinated peptide antibody; ELISA, enzyme-linked immunosorbent assay; MPO, myeloperoxidase; SLA/LP, soluble liver antigen/liver pancreas; LC-1, liver cytosolic antigen type 1; LKM-1, liver kidney microsomal type 1 antibody